Instem Stock

Instem FCF/Debt

Delisted·Nov 20, 2023

The Free Cash Flow to Debt Ratio of Instem (INS.L) as of Aug 13, 2026 is 333.95 %. In the previous year, Free Cash Flow to Debt Ratio was 292.70 % — a change of 14.09% (higher).

FCF/Debt

333.95 %

YoY

14.09%

Last updated:

Free Cash Flow to Debt Ratio of Instem is 2026 333.95 % . Free Cash Flow to Debt Ratio of Instem was 2025 292.70 % . It decreases by 14.09% higher compared to the previous year.
Access this data via the Eulerpool API

Instem Stock analysis

What does Instem do? Instem PLC is a company specialized in providing software solutions for the health and life sciences. It is headquartered in Abingdon, Oxfordshire and operates internationally. The company was founded in 2000 and has been listed on the London Stock Exchange since 2004. Instem's business model is based on helping life science companies optimize and automate their workflows. They offer a wide range of software products tailored to the specific needs of their customers. This includes systems for documenting animal experiments, clinical data collection, and solutions for regulatory drug submissions. One of Instem's key divisions is the Preclinical Solutions Division, which helps life science companies effectively plan and conduct their preclinical studies. The products in this division support the creation of study protocols, planning experimental procedures, and documenting study results. Additionally, customers of the Preclinical Solutions Division can access assistance with data collection and analysis, as well as comprehensive consulting services. Another important division of Instem is the Clinical Solutions Division, which supports clinical research facilities in conducting clinical trials. Their solutions include clinical data collection, study monitoring, and data submission to regulatory authorities. The Clinical Solutions Division also provides support for quality control and the production of statistical reports. Instem is also active in other areas, such as in vitro diagnostics and chemical approval. In these fields, the company offers a range of software solutions that aid in data collection, analysis, and reporting. A key factor that sets Instem apart from its competitors is its close collaboration with the life science community. The company works closely with customers, regulatory agencies, and interest groups to ensure that its products meet industry requirements and standards. In addition, the company has established close relationships with leading clinical and research institutions worldwide. In summary, Instem PLC is a significant provider of software solutions for the health and life sciences. The company has experienced impressive growth in recent years and strengthened its position in key market segments. Instem is well positioned to continue benefiting from the increasing demand for software solutions in the health and life sciences industry. Instem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Instem stock

Free Cash Flow to Debt Ratio of Instem is 333.95 % in 2026.

Free Cash Flow to Debt Ratio of Instem changed from 292.70 % to 333.95 %, representing a 14.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Instem since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Instem with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Instem

All Key Metrics — Instem